Una passeggiate a piedi passato l'edificio dell'ufficio cinese di società farmaceutiche BeiGene a Suzhou Ctiy, est della Cina di Jiangsu Province su Novembre 22nd,

• Collaboratore: Cynthia Lee / Alamy Foto Stock
• ID dell’immagine: 2AB9BDR
• Dimensioni dei file: 37,2 MB (1,6 MB Download compresso)
• Liberatorie: Modello - no | Proprietà - no
• Dimensioni: 4349 x 2987 px | 36,8 x 25,3 cm | 14,5 x 10 inches | 300dpi
• Data acquisizione: 22 novembre 2019

Altre informazioni

A pedestrian walks past the office building of Chinese pharmaceutical company BeiGene in Suzhou Ctiy, east China's Jiangsu Province on November 22nd, 2019. A Chinese pharmaceutical company has won market approval from the United States Food and Drug Administration for a self-developed lymphoma drug, marking the first entry of an innovative cancer drug from a Chinese company into the US and giving a boost to domestic drugmakers' ambitions to create new treatments for patients around the world. The drug, known as Brukinsa, is a product from Beijing-based BeiGene. It received the FDA's approval and is expected to become available to US patients by the end of the year, Wu Xiaobin, BeiGene president, said at a news conference.

Parole chiave associate all'immagine

• baiji
• beigene
• biontech
• bioscience
• biotecnologia
• china
• cinese
• drogue
• farmaceutico